AstraZeneca Submits Atacand For Heart Failure: First ARB To Show Mortality Benefit

Combination use with ACE inhibitors will likely be an issue for the Atacand sNDA; the efficacy seen in AstraZeneca’s CHARM studies conflicts with the Val-HeFT data for Novatis’ angiotensin-II receptor blocker Diovan, which showed no added benefit.